Advances in high‐throughput mass spectrometry in drug discovery
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
High-throughput (HT) screening drug discovery, during which thousands or millions of compounds are screened, remains the key methodology for identifying active chemical matter in early drug discovery pipelines. Recent technological developments in mass spectrometry (MS) and automation have revolutionized the application of MS for use in HT screens. These methods allow the targeting of unlabelled biomolecules in HT assays, thereby expanding the breadth of targets for which HT assays can be developed compared to traditional approaches. Moreover, these label-free MS assays are often cheaper, faster, and more physiologically relevant than competing assay technologies. In this review, we will describe current MS techniques used in drug discovery and explain their advantages and disadvantages. We will highlight the power of mass spectrometry in label-free in vitro assays, and its application for setting up multiplexed cellular phenotypic assays, providing an exciting new tool for screening compounds in cell lines, and even primary cells. Finally, we will give an outlook on how technological advances will increase the future use and the capabilities of mass spectrometry in drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Electrospray Ionization for Mass Spectrometry of Large Biomolecules
Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F., & Whitehouse, C. M. (1989) · Science · doi:10.1126/science.2675315 · Cited by 7,634 · cited 1×
“The solvent of the droplets is vaporized by a drying gas or heat and the charged analytes are guided by a potential gradient toward the analyzer region of the MS (Fenn et al , 1989; El-Aneed et al , 2009).”
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939 · cited 1×
“The historical aspects of the traditional drug discovery pipeline have been extensively reviewed and demonstrate the advantages and challenges of drug discovery throughout R&D including productivity, attrition, and evolution of new technologies (Moffat et al , 2017; Vin-cent et al , 2022).”
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis
Anastasiou, D., Yu, Y., Israelsen, W. J., Jiang, J.-K., Boxer, M. B., Hong, B. S., Tempel, W., Dimov, S., Shen, M., Jha, A., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1060 · Cited by 816 · cited 1×
“This has been particularly impactful where probes were used to explore the therapeutic effects of PKM2 activation in cancer (Anastasiou et al , 2012; Kung et al , 2012), and in the generation of a covalent inhibitor of KRAS that was previously thought to be undruggable (Naim et al , 2021).”
Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening
Resnick, E., Bradley, A., Gan, J., Douangamath, A., Krojer, T., Sethi, R., Geurink, P. P., Aimon, A., Amitai, G., Bellini, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02822 · Cited by 335
Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain
Akçay, G., Belmonte, M. A., Aquila, B., Chuaqui, C., Hird, A. W., Lamb, M. L., Rawlins, P. B., Su, N., Tentarelli, S., Grimster, N. P., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2174 · Cited by 207
Small molecule activation of PKM2 in cancer cells induces serine auxotrophy
Kung, C., Hixon, J., Choe, S., Marks, K., Gross, S., Murphy, E., DeLaBarre, B., Cianchetta, G., Sethumadhavan, S., Wang, X., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.021 · Cited by 192 · cited 1×
“This has been particularly impactful where probes were used to explore the therapeutic effects of PKM2 activation in cancer (Anastasiou et al , 2012; Kung et al , 2012), and in the generation of a covalent inhibitor of KRAS that was previously thought to be undruggable (Naim et al , 2021).”
Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation
Zhang, T., Hatcher, J. M., Teng, M., Gray, N. S., & Kostic, M. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.09.012 · Cited by 178 · cited 1×
“Using small covalent fragments to probe biological systems and poorly characterized targets significantly enhances our ability to translate traditional biological research to the development of new medicines and understanding their MoA (Schreiber Stuart et al , 2015; Zhang et al , 2019).”
Fragment-based covalent ligand discovery
Lu, W., Kostic, M., Zhang, T., Che, J., Patricelli, M. P., Jones, L. H., Chouchani, E. T., & Gray, N. S. (2021) · RSC Chemical Biology · doi:10.1039/d0cb00222d · Cited by 136
Shin, Y., Jeong, J. W., Wurz, R. P., Achanta, P., Arvedson, T., Bartberger, M. D., Campuzano, I. D. G., Fucini, R., Hansen, S. K., Ingersoll, J., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00258 · Cited by 113 · cited 1×
“Many studies have used this technology to screen fragments against various targets such as the E3 ligase HOIP (Johansson et al , 2019), BRD4 (Grant et al , 2019; Olp et al , 2020), GDP-KRAS G12C (Shin et al , 2019), and OTUB2 and NUDT7 (Resnick et al , 2019).”
Cited by
Integrating Computational Design and Experimental Approaches for Next-Generation Biologics
Son, A., Park, J., Kim, W., Lee, W., Yoon, Y., Ji, J., & Kim, H. (2024) · Biomolecules · doi:10.3390/biom14091073 · Cited by 29
The impact of AI on modern oncology from early detection to personalized cancer treatment
Li, J., Zhang, L., Yu, Z., Bao, Z., Li, D., & Wang, L. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01276-6 · Cited by 24
Voronov, G., Lightheart, R., Frandsen, A., Bargh, B., Haynes, S. E., Spencer, E., Schoenhardt, K. E., Davidson, C., Schaum, A., Macherla, V. R., et al. (2022) · doi:10.1101/2022.10.09.511482 · Cited by 18
Lou, X., Zhou, Q., Dong, Z., Bai, L., Su, J., & Yue, H. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.07.010 · Cited by 17
Metadata
- Authors
- Dueñas, M. E., Peltier‐Heap, R. E., Leveridge, M., Annan, R. S., Büttner, F. H., & Trost, M.
- Venue
- EMBO Molecular Medicine
- Published
- 2022-12-14
- Volume
- 15
- Issue
- 1
- Pages
- e14850-e14850
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W4311480785
- Cited by
- 122
- References
- 13
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in high‐throughput mass spectrometry in drug discovery. https://app.cochat.ai/papers/10.15252/emmm.202114850
- The paper
- Dueñas, M. E., Peltier‐Heap, R. E., Leveridge, M., Annan, R. S., Büttner, F. H., & Trost, M. (2023). Advances in high‐throughput mass spectrometry in drug discovery. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202114850
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.